Vidaza Still MDS Winner, But Market Seems Roomy
The clock is ticking on key decisions related to a pair of drugs for myelodysplastic syndrome (MDS) - MGI Pharma Inc.'s Dacogen and Celgene Corp.'s Revlimid - and the market seems ready to widen, even as physicians continue to look fondly upon Pharmion Corp.'s injectable Vidaza (azacitidine), the compound in-licensed from Pharmacia & Upjohn Co., now part of Pfizer Inc.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST